Dashboard
Company has a low Debt to Equity ratio (avg) at 0.03 times
Healthy long term growth as Net Sales has grown by an annual rate of 23.37% and Operating profit at 40.15%
Negative results in Sep 26
Stock is technically in a Bullish range
With ROE of 8.3, it has a Expensive valuation with a 2.7 Price to Book Value
Despite the size of the company, domestic mutual funds hold only 0% of the company
Stock DNA
Pharmaceuticals & Biotechnology
INR 814 Cr (Micro Cap)
32.00
40
0.00%
0.13
8.35%
2.91
Total Returns (Price + Dividend) 
Latest dividend: 0.2446341463414634 per share ex-dividend date: Sep-20-2019
Risk Adjusted Returns v/s 
Returns Beta
News

Kilitch Drugs Upgraded to Hold as Technicals Improve Despite Valuation Concerns
Kilitch Drugs (India) Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its technical outlook amid an expensive valuation and mixed financial trends. The upgrade, effective from 13 Nov 2026, is driven primarily by improved technical indicators, while valuation and financial performance present a more complex picture for investors.
Read More
Kilitch Drugs (India) Ltd Sees Bullish Momentum Shift Amid Technical Upgrades
Kilitch Drugs (India) Ltd has demonstrated a notable shift in technical momentum, with key indicators signalling a transition from a mildly bullish to a bullish trend. The stock’s recent price action, combined with positive signals from MACD, Bollinger Bands, and moving averages, suggests growing investor confidence amid a volatile pharmaceutical sector backdrop.
Read More
Kilitch Drugs Valuation Shifts to Expensive Amid Strong Market Returns
Kilitch Drugs (India) Ltd has witnessed a notable change in its valuation parameters, shifting from a fair to an expensive rating. This development, coupled with its recent price movements and peer comparisons, invites a closer examination of its price attractiveness and investment potential within the Pharmaceuticals & Biotechnology sector.
Read More Announcements 
Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
16-Nov-2026 | Source : BSEWe are submitting Scrutinizers Report for evoting of EGM
Shareholder Meeting / Postal Ballot-Outcome of EGM
16-Nov-2026 | Source : BSEProceeding of EGM held today i.e. 16th November 2026
Announcement under Regulation 30 (LODR)-Newspaper Publication
15-Nov-2026 | Source : BSENewspaper Publication of Corrigendum to EGM Notice
Corporate Actions 
No Upcoming Board Meetings
Kilitch Drugs (India) Ltd has declared 5% dividend, ex-date: 20 Sep 19
No Splits history available
Kilitch Drugs (India) Ltd has announced 1:1 bonus issue, ex-date: 24 Mar 26
Kilitch Drugs (India) Ltd has announced 2:23 rights issue, ex-date: 15 Jul 25
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 2 Schemes (0.0%)
Held by 2 FIIs (0.11%)
Kilitch Company (pharma) Limited (37.92%)
Dipak Kanayalal Shah (3.15%)
29.03%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 11.90% vs -49.91% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is -23.37% vs -79.96% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 13.75% vs 4.08% in Sep 2024
Growth in half year ended Sep 2025 is 12.65% vs 22.96% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 6.40% vs 25.15% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -1.70% vs 44.60% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 18.73% vs 28.47% in Mar 2025
YoY Growth in year ended Mar 2026 is 13.00% vs 82.88% in Mar 2025